Stopping controversial asthma drugs could have downside: study
August 27, 2012 by Randy Dotinga, Healthday Reporter in Immunology
Findings differ from FDA caution on combination therapies.
(HealthDay)—It's OK for some patients with asthma to stick with a combination of medications instead of abandoning one because of concerns about complications, a new analysis of existing research suggests.
The U.S. Food and Drug Administration has warned that asthma patients who take both long-acting beta-agonist and inhaled corticosteroid medications should be cautious about using them together once their condition is under control.
Long-acting beta-agonists—such as drugs known by the brand names Serevent, Foradil and Brovana—could cause side effects, the FDA cautioned, as could combination drugs. For that reason, the agency suggested that patients consider going with inhaled corticosteroids alone.
However, the new analysis came to a different conclusion. "Adding a long-acting beta-agonist to an inhaled corticosteroid medication makes a lot of sense in a number of patients since you get better control of the disease," said Dr. Thomas Casale, chief of allergy and immunology at Creighton University, and lead author of the report.
The report was published online Aug. 27 in the journal Archives of Internal Medicine.
At issue is how to best treat adults and older children who suffer from moderate to severe asthma.
Inhaled corticosteroids, which come in inhalers and are known by brand names such as Azmacort and Flovent, are often prescribed by themselves to reduce wheezing and other symptoms. They're usually taken daily but don't relieve asthma attacks when they're occurring. (Short-acting beta-agonists, such as the drug albuterol, treat asthma attacks themselves.)
The newer long-acting beta-agonists are frequently used with inhaled corticosteroids. Some medications, sold under the brand names Symbicort and Advair, combine both types of drugs.
This latest analysis, which examined five studies involving patients aged 15 or older, found that removing a long-acting beta-agonist—but continuing treatment with an inhaled corticosteroid—was worse for patients than continuing both drugs.
Patients who dropped the long-acting beta-agonists reported more asthma problems and fewer days with no symptoms. The findings also suggested that these patients needed more treatment of asthma attacks. The studies, however, didn't allow researchers to examine the risk of death under the different approaches.
Casale said he doesn't think the FDA's concerns about death and other health problems—which resulted in a bold warning on drug labels— have deterred physicians from prescribing the combination treatments. However, he said, they have reinforced guidelines recommending against using the long-acting beta-agonists as treatments by themselves.
"I think all of us agree with that," he said. "They're only to be used in conjunction with an inhaled corticosteroid, and only in those who aren't adequately controlled."
In an accompanying journal editorial, Dr. Chee Chan and Dr. Andrew Shorr, both from the division of pulmonary and critical care medicine at Washington Hospital Center in Washington D.C., wrote that they hoped the analysis "helps to lift some of the black clouds" in the debate over the use of the asthma drugs.
More information: For more about asthma, visit the U.S. National Library of Medicine.
Journal reference:
JAMA Internal Medicine
Copyright © 2012 HealthDay. All rights reserved.
-
Combined asthma medication therapy shown to reduce attacks
Feb 06, 2012 |
not rated yet |
0
-
Against expectations, genetic variation does not alter asthma treatment response
Nov 24, 2009 |
not rated yet |
0
-
Possible alternate therapy for adults with poorly controlled asthma
Sep 19, 2010 |
not rated yet |
0
-
FDA issues warning on 4 widely-used asthma drugs
Feb 18, 2010 |
not rated yet |
0
-
CER study demonstrated asthma patients had better overall results with oral controllers
Aug 26, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Calculating Steam Pressure in Closed Container
5 hours ago
-
Learning curve of Electromagnetism?
10 hours ago
-
thin glass in liquid
11 hours ago
-
How many joules expended for a push up?
14 hours ago
-
force to keep the folding doors
14 hours ago
-
Confusion regarding direction of kinetic friction on inclined plane.
15 hours ago
- More from Physics Forums - Classical Physics
More news stories
Stem-cell-based strategy boosts immune system in mice
Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...
Immunology
May 16, 2013 |
4.8 / 5 (5) |
0
|
Resistance to visceral leishmaniasis: New mechanisms involved
Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...
Immunology
May 16, 2013 |
not rated yet |
0
Women's immune systems remain younger for longer
Women's immune systems age more slowly than men's, suggests research in BioMed Central's open access journal Immunity & Ageing. The slower decline in a woman's immune system may contribute to women living longer than men. ...
Immunology
May 14, 2013 |
not rated yet |
0
Newly described type of immune cell and T cells share similar path to maturity, according to new study
(Medical Xpress)—Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that ...
Immunology
May 14, 2013 |
5 / 5 (3) |
0
|
Not all cytokine-producing cells start out the same way, study finds
(Medical Xpress)—Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory ...
Immunology
May 13, 2013 |
5 / 5 (1) |
0
|
Consuming coffee linked to lower risk of detrimental liver disease, study finds
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...
Ketamine shows significant therapeutic benefit in people with treatment-resistant depression
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...
New research identifies risks, interventions for children's GI health
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
US psychiatry gets makeover in new manual
The latest makeover to a massive psychiatric tome honored by some, reviled by others and even called the "Bible" of mental disorders is being released Saturday with a host of new changes.
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
New case of SARS-like virus in Saudi: ministry
A new case of the deadly coronavirus has been detected in Saudi Arabia where 15 people have already died after contracting it, the health ministry announced on Saturday on its Internet website.